Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | STAT1 | P42224 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8698425 | 0.81 | ATP4A (0.57) | HSD17B10MAPTNPC1RAB9ASTAT1 | |
| SCHEMBL19625320 | 0.81 | HSD17B10 (0.60) | HSD17B10LMNAMAPTNPC1RAB9A | |
| SCHEMBL30263272 | 0.79 | HSD17B10 (1.00) | HSD17B10LMNAMAPTNPC1RAB9A | |
| SCHEMBL39119 | 0.79 | HSD17B10 (1.00) | HSD17B10LMNAMAPTNPC1RAB9A | |
| SCHEMBL4437476 | 0.78 | CYP19A1 (0.57) | LMNAMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17274042 | 0.78 | MAPT (0.46) | HSD17B10MAPTNPC1RAB9ASTAT1 | |
| SCHEMBL1093303 | 0.78 | SMN1; SMN2 (0.60) | HSD17B10MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6366682 | 0.78 | RECQL (0.51) | HSD17B10MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13475977 | 0.78 | GRM5 (0.54) | MAPTRAB9ASMN1; SMN2RECQLTSHR | |
| SCHEMBL4398658 | 0.78 | HSD17B10 (0.66) | HSD17B10LMNAMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022256419-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | WNT1, WNT3A, CTNNB1 | HSD17B10 2524/4885LMNA 2300/4885MAPT 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.